Journal profile · Oncology
Nature reviews. Cancer
ISSN 1474-175X · eISSN 1474-1768 · Springer Nature · ENGLAND · Monthly · Founded 2001
Nature reviews. Cancer: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 60.46; subscription journal; review 6–12 weeks (community reports); community-reported acceptance: mostly invited papers; 115 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Nature reviews. Cancer is published by Springer Nature and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Genomics and Diagnostics, Epigenetics and DNA Methylation and Cancer Cells and Metastasis, together about 26.8% of its articles. Its main subfields are Molecular Biology and Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Nature Reviews Cancer aims to be the premier source of reviews and commentaries for the scientific communities we serve. We strive to publish articles that are authoritative, accessible and enhanced with clearly understandable figures, tables and other display items. We want to provide an unparalleled service to authors, referees and readers, and we work hard to maximize the usefulness and impact of each article. The journal publishes Research Highlights, Comments, Reviews and Perspectives relevant to cancer researchers, with our broad scope ensuring that the articles we publish reach the widest possible audience. Nature Reviews Cancer is part of the Nature Reviews portfolio of journals. To learn more about Nature Reviews, check out this animation and the Nature Reviews page. You can also find a summary of the editorial input and checks here.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editorial board by country: none in mainland China; most named United Kingdom 10, Germany 3, United States 1, India 1, Italy 1 (17 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology10.1%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology9.6%
- Cancer Cells and MetastasisMedicine7.1%
- Cancer-related Molecular PathwaysMedicine7%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology6.1%
- Ubiquitin and proteasome pathwaysBiochemistry, Genetics and Molecular Biology5.8%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology4.2%
- DNA Repair MechanismsBiochemistry, Genetics and Molecular Biology3.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 60.46LetPub ·
- CiteScore 2026-06
- 96.2LetPub ·
- SJR 2026-06
- 22.81LetPub ·
- SNIP 2026-06
- 10.57LetPub ·
- h-index
- 396LetPub ·
- h-index
- 602OpenAlex ·
- i10-index
- 1,781OpenAlex ·
- 2-year mean citedness
- 26.58OpenAlex ·
- Self-citation rate
- 0.7%LetPub ·
- Share of gold OA articles
- 2.14%LetPub ·
Volume
- Articles per year
- 48LetPub ·
Articles by year OpenAlex count · 4,709 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 84 | 8 | 215 |
| 2025 | 115 | 25 | 2,443 |
| 2024 | 129 | 29 | 6,059 |
| 2023 | 112 | 19 | 9,061 |
| 2022 | 108 | 32 | 15,090 |
| 2021 | 111 | 31 | 24,669 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Mostly invited papersLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 2001
- ISSN
- 1474-175X
- Electronic ISSN
- 1474-1768
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Nature reviews. Cancer
What CAS zone is Nature reviews. Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, Nature reviews. Cancer is in Zone 1 of Medicine, and in Zone 1 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Nature reviews. Cancer?
The latest impact factor listed by LetPub is 60.46; CiteScore 96.2, h-index 602.
How long does peer review take at Nature reviews. Cancer?
Authors report an average review time of 6–12 weeks; the community-reported acceptance is “Mostly invited papers”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Nature reviews. Cancer based?
Of the 17 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United Kingdom (10), Germany (3) and United States (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Nature reviews. Cancer?
According to LetPub and DOAJ records, Nature reviews. Cancer is indexed in SCIE and Scopus.
Is Nature reviews. Cancer open access, and what is the APC?
Nature reviews. Cancer is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .